JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M306744200 on October 21, 2003

J. Biol. Chem., Vol. 278, Issue 52, 52497-52503, December 26, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/52/52497    most recent
M306744200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rong, R.
Right arrow Articles by Ye, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rong, R.
Right arrow Articles by Ye, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phospholipase Activity of Phospholipase C-{gamma}1 Is Required for Nerve Growth Factor-regulated MAP Kinase Signaling Cascade in PC12 Cells*

Rong Rong{ddagger}, Jee-Yin Ahn{ddagger}, Peng Chen{ddagger}, Pann-Ghill Suh§, and Keqiang Ye{ddagger}

From the {ddagger}Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322 and the §Department of Life Science, Division of Molecular Life Science, Pohang University of Science and Technology, San 31 Hyojadong Pohang 790-784, Korea

Received for publication, June 25, 2003 , and in revised form, October 17, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Phospholipase C-{gamma}1 (PLC-{gamma}1) hydrolyzes phosphatidylinositol 4,5-bisphosphate to the second messengers inositol 1,4,5-trisphosphate and diacylglycerol (DAG). PLC-{gamma}1 is implicated in a variety of cellular signalings and processes including mitogenesis and calcium entry. However, numerous studies demonstrate that the lipase activity is not required for PLC-{gamma}1 to mediate these events. Here, we report that the phospholipase activity of PLC-{gamma}1 plays an essential role in nerve growth factor (NGF)-triggered Raf/MEK/MAPK pathway activation in PC12 cells. Employing PC12 cells stably transfected with an inducible form of wild-type PLC-{gamma}1 or lipase inactive PLC-{gamma}1 with histidine 335 mutated into glutamine in the catalytic domain, we show that NGF provokes robust activation of MAP kinase in wild-type but not in lipase inactive cells. Both Ras/C-Raf/MEK1 and Rap1/B-Raf/MEK1 pathways are intact in the wild-type cells. By contrast, these signaling cascades are diminished in the mutant cells. Pretreatment with cell permeable DAG analog 1-oleyl-2-acetylglycerol rescues the MAP kinase pathway activation in the mutant cells. These observations indicate that the lipase activity of PLC-{gamma}1 mediates NGF-regulated MAPK signaling upstream of Ras/Rap1 activation probably through second messenger DAG-activated Ras and Rap-GEFs.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Growth factor stimulation triggers phospholipase C-{gamma}1 (PLC-{gamma}1)1 membrane translocation and association with receptor-tyrosine kinase through coupling between the phosphotyrosine docking site on receptor-tyrosine kinase and SH2 domain of PLC-{gamma}1, resulting in tyrosine phosphorylation and activation of its enzymatic activity. When activated, PLC-{gamma}1 provokes the hydrolysis of phosphatidylinositol 4,5-P2 to produce two second messenger molecules: inositol 1,4,5-trisphosphate and DAG, which regulate the intracellular Ca2+ and activation of protein kinase C, respectively. PLC-{gamma}1 plays a critical role in cell proliferation and differentiation. In mouse, PLC-{gamma}1 is essential for embryonic development, as disrupted plcg1 alleles produce embryonic lethality at approximately day 9.0 (1). Furthermore, disruption of the plcg1 gene in Drosophila is not lethal but leads to abnormal eye development (2). Micro-injection of PLC-{gamma}1 induces DNA synthesis in quiescent NIH 3T3 cells, and antibodies to PLC-{gamma}1 can inhibit serum- and Ras-stimulated DNA synthesis in NIH 3T3 cells (3, 4). However, multiple studies demonstrate that the mitogenic activity of PLC-{gamma}1 is not dependent on its phospholipase activity, but requires its SH3 domain (5–7). Recently, we have shown that PLC-{gamma}1, through its SH3 domain, is a physiologic guanine nucleotide exchange factor (GEF) for PIKE (PI 3-kinase enhancer), a nuclear GTPase that activates nuclear phosphoinositide 3-kinase activity and mediates the physiologic activation by NGF for nuclear phosphoinositide 3-kinase activity (8, 9). Presumably, such mitogenic activity is associated with the activation by PIKE of nuclear phosphoinositide 3-kinase. In addition, the lipase activity is not needed for other major effects either, for example, the SH3 domain but not the lipase activity of PLC-{gamma}1 has been shown to mediate agonist-induced Ca2+ entry in PC12 cells (10).

The mitogen-activated protein/extracellular signal-regulated kinases (MAP kinases or ERKS) regulate a diverse array of functions, such as cell growth and proliferation, differentiation, and apoptosis (11). Upon activation, the ERK/MAPKs translocate to the nucleus to phosphorylate several transcription factors including Elk-1, NF-IL6/C/EBP/NF-M, and Tal-1 (12–14). NGF treatment induces differentiation of PC12 cells into a sympathetic neuron-like phenotype, and this effect is regulated by the sustained activation of ERKs. In PC12 cells, NGF triggers both transient and sustained MAP kinase signalings, which are regulated through two distinct small GTPases Ras and Rap1. The activated Ras and Rap1 stimulate sequential activation of Raf serine/threonine kinases C-Raf and B-Raf, respectively, which in turn activate MEK1/ERKs. The transient activation of Ras is regulated through its association with an adaptor complex consisting of Shc/Grb2/Sos. While the prolonged activation of ERK signaling depends on a distinct pathway initiated through NGF receptor TrkA binding to fibroblast growth factor receptor substrate 2, whose tyrosine residues are phosphorylated and provide docking sites for adaptor protein Crk, which in turn binds and activates the C3G GEF. The activated C3G subsequently provokes Rap-1/B-Raf/MEK/ERK signaling (15).

Numerous studies indicate that there is cross-talk between the MAPK pathway and PLC-{gamma}1 signaling cascade. For instance, elimination of the Shc binding site in NGF receptor TrkA reduces NGF-induced differentiation of PC12 cells. However, total abrogation of differentiation is observed when both Shc and PLC-{gamma}1 binding sites are eliminated (16, 17). Therefore, both Shc-mediated Ras-dependent and PLC-{gamma}1-dependent pathways are essential for NGF-induced differentiation of PC12 cells. In addition, it has been shown before that PLC-{gamma}1 mediates fibroblast growth factor-initiated C-Raf/MAPK activation through protein kinase C (18). Studies have also shown that it binds the Ras GEF Sos and enhances Ras activity (19–21). In addition, the SH3 domain of PLC-{gamma}1 has been revealed to bind the proline-rich domain of SLP-76, and this interaction is required for T cell receptor-mediated activation of ERK, and nuclear factor of activated T cells (22). However, none of these studies explicitly defines the role of phospholipase activity of PLC-{gamma}1 in MAPK signaling. Utilizing stable-inducible wild-type and lipase inactive PLC-{gamma}1-(H335Q) PC12 cells, we demonstrate that the phospholipase activity of PLC-{gamma}1 is required for NGF-triggered activation of the Raf/MEK/MAPK pathway. Our results indicate that the lipase activity of PLC-{gamma}1 plays a critical role for some aspects of cellular signaling.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cells and Reagents—PC12 cells were maintained in medium A (Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 5% horse serum, and 100 units penicillin-streptomycin) at 37 °C with 5% CO2 atmosphere in a humidified incubator. The FLAG-tagged PLC-{gamma}1 stably transfected PC12 cells (Tet-off cell line) were cultured in medium B (Dulbecco's modified Eagle's medium, 10% horse serum, 5% fetal bovine serum, 100 µg/ml G418, 100 µg/ml hygromycin B, 2 µg/ml tetracycline, and 100 units of penicillin-streptomycin). PLC-{gamma}1 was induced in medium without tetracycline for 24 h. Mouse monoclonal anti-HA, anti-Myc, anti-Ras antibodies, Protein A/G-conjugated agarose beads, U73122 [GenBank] , and U73343 [GenBank] were from Calbiochem. Anti-PLC-{gamma}1, anti-Rap1, anti-B-Raf, anti-c-Raf, and anti-ERK1/2 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-ERK was from New England Biolabs. Anti-phosphotyrosine 4G10 was from Upstate Biotechnology Inc. (Lake Placid, NY). Anti-FLAG and anti-Myc horseradish peroxidase-conjugated antibodies were from Sigma. myo-[2-3H]Inositol and [3H]phosphoinositide 4,5-P2 were from PerkinElmer Life Sciences. All chemicals not included above were from Sigma.

Assay for PLC Activity—NGF-treated PC12 cells were lysed in an extraction buffer composed of 50 mM Tris, pH 7.4, 40 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium pyrophosphate, 10 mM sodium {beta}-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, and centrifuged for 10 min at 14,000 x g at 4 °C. After normalizing the protein concentration, 2 µg of anti-PLC-{gamma}1 antibody and 40 µl of 50% slurry Protein A/G-agarose (Calbiochem) were added to the supernatant and incubated with rotation at 4 °C for 3 h. The agarose pellet was washed three times with buffer containing 5 mM Tris-HCl, pH 7.0, 0.75 mM KCl, 0.416 mM CaCl2, 0.4 mM EGTA, 0.1 mM NaN3. The assay was performed as described previously using liposomes containing 30 µM cholesterol, 50 µM phosphatidylcholine, 30 µM phosphatidylethanolamine, 5 µM phosphoinositide 4,5-P2, 25,000 dpm of labeled [3H]phosphoinositide 4,5-P2, and 10 µM profiling (23). For the in vivo PLC-{gamma}1 activity assay, induced and uninduced PC12 cells were labeled with myo-[2-3H]inositol (2 µCi/ml, PerkinElmer Life Sciences) in inositol-free medium for 24 h. The labeled cells were pre-treated with 20 mM LiCl for 15 min in serum-free Dulbecco's modified Eagle's medium containing 1 mg/ml bovine serum albumin. Cells were then stimulated by NGF for the indicated times. The reaction was terminated by the addition of 0.6 ml of ice-cold 5% HClO4. After 30 min on ice, the extract was eluted through a Bio-Rad Dowex AG 1-X8 anion exchange column. Total inositol phosphate was eluted with a solution containing 1 M ammonium formate and 0.1 M formic acid, and quantified by liquid scintillation counting.

Ras Binding Domain Affinity Binding Assay—PC12 cells were lysed in the Ras/Rap1 binding domain (RBD) assay buffer containing 50 mM Tris, pH 7.5, 10 mM MgCl2, 1% Triton, 0.25% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, and leupeptin. The lysates (3 mg of protein) were incubated with 30 µg of glutathione S-transferase (GST)-C-Raf-RBD at 4 °C for 45 min. The affinity precipitates were washed 3 times with lysis buffer and eluted with Laemmli sample buffer. Proteins were resolved on 12% SDS-PAGE. Western blotting analysis was performed with anti-Ras antibody.

Raf Kinase Assay—Full details of the procedure were previously described (24). Briefly, rabbit polyclonal anti-Raf-1 antibodies or preimmune serum were incubated with cell lysates for 1 h at 4 °C. The immunocomplexes were bound to Protein A/G-agarose beads for an additional 1 h. The beads were washed with 0.5 M LiCl solution, resuspended in 38 µl of buffer (25 mM Tris-HCl, pH 7.5, 10 mM MnCl2, 10 µM ATP, 1 mM dithiothreitol, 25 mM {beta}-glycerophosphate), 1 µl of 4 mM Syntide II peptide, and 0.1 µCi of [{gamma}-32P]ATP, and incubated for 20 min at room temperature. The reaction mixture was spotted onto Whatman P81 paper and air-dried. The paper was washed extensively with 0.85% phosphoric acid and counted in scintillation liquid.

Preparation of RalGDS(RBD) Fusion Protein—The pGEX-RalGDS(RBD) plasmid encoding a GST fusion protein containing the 97-amino acid RBD of the RalGDS protein and its purification have been described previously (25).

Rap1 Activation Assay—Bacterial lysate (20 µl per sample) containing the GST-RalGDS(RBD) fusion protein was mixed with glutathione-Sepharose 4B beads for 1–2 h in the cold. After washing the beads twice with Nonidet P-40 lysis buffer, cell lysates were added and mixed with the beads for 1 h. The beads were then washed three times with Nonidet P-40 lysis buffer, and bound proteins were resolved with SDS-PAGE sample buffer containing 100 mM dithiothreitol. Eluted proteins were separated by SDS-PAGE, transferred to nitrocellulose, and analyzed with 1 µg/ml anti-Rap1 antibody by Western blotting.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
H335Q Mutation in the Catalytic Domain of PLC-{gamma}1 Diminishes NGF-mediated Phospholipase Activity—To explore the effect of phospholipase activity of PLC-{gamma}1 in NGF signaling, we employed tet-off PC12 cells stably transfected with the inducible form of FLAG-tagged PLC-{gamma}1-WT and PLC-{gamma}1-(H335Q), designated as PLC-{gamma}1-LIM. A point mutation in the X-catalytic domain of PLC-{gamma}1 (His335 -> Gln) is catalytically inactive when expressed in mammalian cells (7). To examine whether the inducible PLC-{gamma}1-LIM could inhibit NGF-triggered phospholipase activity, we performed an in vitro lipase activity assay utilizing [3H]phosphatidylinositol 4,5-P2 as a substrate, and normalized the enzymatic activity against empty vector-uninduced cells. When induced in the absence of tetracycline, cells transfected with wild-type PLC-{gamma}1 display almost 1-fold augmentation of lipase activity even in the absence of NGF treatment compared with empty vector-transfected control cells. NGF treatment for 5 min for these cells leads to a further enhancement of PLC-{gamma}1 activation, and the activity decreases somewhat at 30 min. By contrast, the lipase inactive mutant displays only 50% activity compared with control cells even without NGF stimulation, consistent with earlier findings (26). Compared with the control and PLC-{gamma}1-WT cells, the lipase activity in the PLC-{gamma}1-LIM cells is markedly inhibited in response to NGF stimulation (Fig. 1A). However, we observed essentially similar lipase activity in the uninduced PC12 cells (Fig. 1B). Expression of induced FLAG-tagged PLC-{gamma}1 was verified (Fig. 1C). Tyrosine phosphorylation plays a critical role for the activation of PLC-{gamma}1 (27). To determine whether cells transfected with PLC-{gamma}1-LIM possess distinct tyrosine phosphorylation, we monitored tyrosine phosphorylation of PLC-{gamma}1 immunoprecipitated by anti-FLAG antibody (Fig. 1D). We observed a similar tyrosine phosphorylation effect upon NGF treatment in both PLC-{gamma}1-WT and -LIM cells, indicating that the upstream signaling from NGF receptor TrkA to PLC-{gamma}1 is intact in the lipase inactive mutant-transfected cells. To further evaluate the phospholipase activity in intact cells, we cultured both induced and uninduced cells in inositol-free medium supplemented with myo-[2-3H]inositol, and stimulated with NGF for various time points. PLC-{gamma}1 activity analysis reveals similar results as in the in vitro assay (Fig. 1, E and F). The expression of PLC-{gamma}1 in both induced and uninduced cells is shown (Fig. 1, G and H). We have observed similar effects in different clones of cells (data not shown). These data indicate that the exogenously expressed PLC-{gamma}1 mutant acts in a dominant-negative manner despite expression of endogenous PLC-{gamma}1.



View larger version (48K):
[in this window]
[in a new window]
  		FIG. 1.
H335Q mutation in the catalytic domain of PLC-{gamma}1 diminishes NGF-mediated phospholipase activity. A and B, H335Q mutation abolishes NGF-triggered phospholipase activity of PLC-{gamma}1 in vitro. Cells transfected with empty vector, PLC-{gamma}1-WT, or PLC-{gamma}1-LIM were cultured in the absence (induced) or presence (non-induced) of tetracycline for 24 h, before 100 ng/ml NGF was added. PLC-{gamma}1 was immunoprecipitated and analyzed with a in vitro lipase activity assay employing [3H]phosphoinositide 4,5-P2 as substrate. C, equal amounts of FLAG-tagged PLC-{gamma}1 expression was verified by Western blotting with anti-FLAG antibody. D, NGF provokes tyrosine phosphorylation of both PLC-{gamma}1-WT and PLC-{gamma}1-LIM. The induced FLAG-tagged PLC-{gamma}1-WT and PLC-{gamma}1-LIM were immunoprecipitated and analyzed with mouse monoclonal phosphotyrosine antibody (bottom panel). Equal amounts of induced FLAG-tagged PLC-{gamma}1 were immunoprecipitated (top panel). E and F, H335Q mutation abolishes the NGF-triggered phospholipase activity of PLC-{gamma}1 in stably transfected PC12 cells. Cells were cultured in inositol-free medium supplemented with myo-[2-3H]inositol in the presence or absence of tetracycline for 24 h, and stimulated with 100 ng/ml NGF for various times. Total inositol phosphate was analyzed by liquid scintillation counting. G and H, endogenous and induced PLC-{gamma}1 expression was verified by Western blotting with anti-PLC-{gamma}1 antibody.

 
MEK1/MAP Kinase Signaling Is Abrogated in PC12 Cells Transfected with PLC-{gamma}1-LIM—To evaluate the effect of phospholipase activity of PLC-{gamma}1 on the NGF-mediated MAP kinase cascade, we monitored the activation of MAP kinase using anti-phospho-ERK1/2 antibody. Cells transfected with PLC-{gamma}1-WT display higher MAP kinase activity compared with control cells even in the absence of NGF, and NGF treatment elicits further stimulation. In contrast, MAP kinase activity is diminished in cells transfected with PLC-{gamma}1-LIM (Fig. 2A). Consistent with this observation, pretreatment with 10 µM PLC inhibitor U73122 [GenBank] but not its inactive analog U73433 [GenBank] also inhibits NGF-stimulated MAP kinase activation (data not shown). However, other MAP kinase family members including JNK1 and p38 are not activated in any of these cells. Moreover, phosphoinositide 3-kinase signaling is intact in these cells, as demonstrated by the phosphorylation of Akt (Fig. 2B). Equal amounts of FLAG-tagged PLC-{gamma}1 constructs are expressed (Fig. 2C). Different stable clones display similar effect upon NGF treatment (Fig. 2D). This observation, combined with diminished phospholipase activity in PLC-{gamma}1-LIM cells, suggests that the overexpressed PLC-{gamma}1-LIM-(H335Q) mutant is acting in a dominant-negative manner. Moreover, the PLC-{gamma}1 metabolic products diacylglycerol and inositol 1,4,5-trisphosphate might somehow contribute to NGF-elicited MAP kinase activation through mediating the upstream machinery. For example, NGF activates a DAG-regulated protein kinase, protein kinase C-{delta}, which appears to act between Raf and MAPK/ERK and is required for activation of MAPK cascade (28).



View larger version (51K):
[in this window]
[in a new window]
  		FIG. 2.
MEK1/MAP kinase signaling is abrogated in PC12 cells transfected with PLC-{gamma}1-LIM. A, PLC-{gamma}1-LIM reduces NGF-mediated MAP kinase activation. Cells transfected with empty vector, PLC-{gamma}1-WT, or PLC-{gamma}1-LIM were cultured in the absence of tetracycline for 24 h, before 100 ng/ml NGF was added. MAP kinase activation was analyzed with phospho-ERK antibody. Overexpression of PLC-{gamma}1-WT slightly enhances MAP kinase activation compared with control cells. By contrast, PLC-{gamma}1-LIM markedly diminishes it. B, verification of the expression of FLAG-tagged PLC-{gamma}1-WT and PLC-{gamma}1-LIM by Western blotting analysis. C, MAP kinase family members JNK1 or p38 are not activated by NGF in any of these cells. NGF-stimulated Akt phosphorylation is not influenced by PLC-{gamma}1 in these cells. D, different stable clones display similar MAPK activation effects upon NGF stimulation. E, EGF-mediated MAP kinase activation is not affected by PLC-{gamma}1-LIM. Cells transfected with PLC-{gamma}1-WT or PLC-{gamma}1-LIM were cultured in the absence of tetracycline for 24 h, before 50 ng/ml EGF was added. MAP kinase activation was analyzed with phospho-ERK antibody. F, MEK1 activation is abrogated in PLC-{gamma}1-LIM cells. Cells transfected with empty vector, PLC-{gamma}1-WT, or PLC-{gamma}1-LIM were cultured in the absence of tetracycline for 24 h, before 100 ng/ml NGF was added. MEK1/2 kinase activation was analyzed with phospho-MEK1/2 antibody (top panel). An equal amount of MEK1/2 was employed in this analysis (bottom panel).

 
NGF induces rapid and sustained MAPK signaling, whereas EGF stimulates transient MAP kinase activation in PC12 cells. To determine whether phospholipase activity of PLC-{gamma}1 plays any role in EGF-provoked MAPK pathway, we examined the activation of MAP kinase using anti-phospho-ERK1/2 antibody. Cells expressing PLC-{gamma}1-WT and PLC-{gamma}1-LIM reveal the same MAP kinase activity (Fig. 2E, upper panel). Similar amounts of MAP kinases are employed in Western blotting analysis (Fig. 2E, bottom panel). These data indicate that PLC-{gamma}1 is specifically implicated in NGF but not EGF-stimulated ERK1/2/MAP kinase activation.

p44/42 MAPK (ERK1 and ERK2) are activated by MEK1/2 through phosphorylation of Thr-202 and Tyr-203. To determine whether the diminished MAPK activation results from the abrogated upstream MEK1/2 kinase, we examined the phosphorylation status of MEK1/2 in these cells. Induction of PLC-{gamma}1-WT substantially enhances the activation of MEK1/2 compared with the control cells. By contrast, the phosphorylation of MEK1/2 is completely inhibited in cells transfected with PLC-{gamma}1-LIM, although equal levels of MEK1/2 are expressed in these cells (Fig. 2F), suggesting that upstream Raf signaling of MEK1/2 is affected by the phospholipase activity of PLC-{gamma}1.

NGF-stimulated Raf Kinase Activation Is Blocked in PLC-{gamma}1-LIM Cells—PC12 cells express two members of the Raf family, B-Raf and C-Raf, both of which have been shown to be activated by NGF treatment as a consequence of their membrane translocation (29, 30). To explore the effect of phospholipase activity of PLC-{gamma}1 on Raf kinases, we examined the activity of both B-Raf and C-Raf kinases utilizing Syntide II peptide as a substrate. NGF-triggered Raf kinase activity is markedly blocked in PLC-{gamma}1-LIM cells compared with empty vector or PLC-{gamma}1-WT expressed PC12 cells (Fig. 3A). Both B-Raf and C-Raf kinases are substantially inhibited in cells expressing PLC-{gamma}1-LIM even in the absence of NGF treatment, indicating that phospholipase activity of PLC-{gamma}1 determines the basal, physiologic activity of Raf kinases as well as being responsible for its response to growth factor stimulation. B-Raf kinase displays higher activity than C-Raf in both cells, consistent with previous findings that NGF-stimulated MAP kinase activation is predominantly contributed by B-Raf (31). However, we observed similar Raf kinase activity in uninduced PC12 cells with higher B-Raf activity than C-Raf (data not shown). These observations suggest that signaling upstream of the Raf kinase is influenced by phospholipase activity of PLC-{gamma}1.



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 3.
NGF-stimulated Raf kinase activation is blocked in PLC-{gamma}1-LIM cells. Raf kinase activity is reduced in PLC-{gamma}1-LIM cells. Cells transfected with empty vector, PLC-{gamma}1-WT, or PLC-{gamma}1-LIM were induced for 24 h, before NGF was introduced. B-Raf and C-Raf were, respectively, immunoprecipitated and analyzed with in vitro kinase assay utilizing Syntide II peptide as a substrate in the presence of 0.1 µCi of [{gamma}-32P]ATP.

 
Phospholipase Activity of PLC-{gamma}1 Mediates NGF-stimulated Ras and Rap1 Activation—In NGF-stimulated PC12 cells, CRaf activation is essentially mediated by Ras, whereas B-Raf is predominantly regulated by Rap1 (15, 32). To investigate whether small GTPases Ras and Rap1 are interfered by the phospholipase activity of PLC-{gamma}1, we performed in vitro Ras and Rap1 activation assays employing RBDs of C-Raf and B-Raf to bind the activated, GTP-bound forms of Ras and Rap1. We observed robust association between Ras/Rap1 and GST-CRaf-RBD/GST-RalGDS in cells expressing PLC-{gamma}1-WT even without NGF stimulation. NGF treatment further augments the interaction, and binding activity decreases after 30 min stimulation. However, we observed very faint Ras/Rap1 activity in cells expressing PLC-{gamma}1-LIM compared with cells transfected with control vector or PLC-{gamma}1-WT whether or not the cells were stimulated with NGF (Fig. 4). Metabolic labeling of PC12 cells with [32P]orthophosphate reveals similar results, NGF stimulation incurs more GTP bound Ras/Rap1 in cells expressing PLC-{gamma}1-WT than PLC-{gamma}1-LIM (data not shown). These observations demonstrate that phospholipase activity of PLC-{gamma}1 mediates NGF-stimulated GTPase Ras and Rap1 activation in PC12 cells.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 4.
Phospholipase activity of PLC-{gamma}1 mediates NGF-stimulated GTPase Ras and Rap1 activation. Cells transfected with PLC-{gamma}1-WT or PLC-{gamma}1-LIM were induced in the absence of tetracycline for 24 h, before 100 ng/ml NGF was added. At different time points, cells were lysed and analyzed with in vitro Ras and Rap1 activation assays employing GST-C-Raf-RBD and GST-RalGDS.

 
Diacylglycerol Analog 1-Oleyl-2-acetylglycerol (OAG) Rescues MAPK Signaling Cascade in PLC-{gamma}1-LIM Cells—Ras/C-Raf/MEK1/2/MAPK and Rap1/B-Raf/MEK1/2/MAPK signaling cascades are impaired in cells transfected with PLC-{gamma}1-LIM but not PLC-{gamma}1-WT, indicating that enzymatic activity of PLC-{gamma}1 is required for NGF to provoke the complete activation of the MAPK pathway. To explore whether addition of the PLC-{gamma}1 hydrolysis product could restore MAPK signaling in PLC-{gamma}1-LIM-transfected PC12 cells, we utilized a cell permeable synthetic diacyglycerol analog, OAG. FLAG-PLC-{gamma}1-LIM was induced in the absence of tetracycline for 24 h, and pretreated with 5 µM OAG or vehicle solvent Me2SO as a control for 30 min before NGF was introduced. Rap1 and Ras activation assays reveal marked activation of Rap1 and Ras even in the absence of NGF. NGF treatment further enhances both Rap1 and Ras activity. By contrast, NGF triggers modest augmentation of Rap1 and Ras activity in Me2SO-treated control cells (Fig. 5A). Quantitative analysis from three independent experiments reveals that OAG-triggered Ras/Rap1 activation is still NGF dependent (Fig. 5B). These data demonstrate that the metabolic product of PLC-{gamma}1 is required to rescue NGF-mediated small GTPase Rap1 and Ras activation. To further test whether the downstream Raf kinases activation is also rescued by OAG, we monitored B-Raf and C-Raf kinase activity in the presence of OAG and Me2SO. Pretreatment with OAG but not Me2SO renders PLC-{gamma}1-LIM cells to activate both B-Raf and C-Raf in response to NGF treatment (Fig. 5C). Consequently, MAP kinase is also robustly activated by NGF in OAG but not Me2SO pretreated PLC-{gamma}1-LIM cells (Fig. 5D, top panel). As a control, we observed the same activity of MAP kinase in empty vector-transfected control cells pretreated with Me2SO or OAG (Fig. 5D, bottom panel). In the absence of NGF, pretreatment with OAG alone slightly stimulates the MAPK cascade presumably through activating DAG binding RasGRF and RapGRF. Quantitative analysis from three independent experiments reveals that OAG-stimulated ERK activation is still NGF dependent (Fig. 5E). These data strongly suggest that phospholipase activity of PLC-{gamma}1 mediates NGF-stimulated MAPK cascade in PC12 cells.



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 5.
Diacylglycerol analog OAG rescues the MAPK signaling cascade in PLC-{gamma}1-LIM cells. A, OAG treatment rescues NGF-mediated Ras and Rap1 activation in PLC-{gamma}1-LIM cells. PC12 cells transfected with PLC-{gamma}1-LIM were induced in the absence of tetracycline for 24 h, and preincubated with 5 µM OAG for 30 min, as a control the same volume of Me2SO (DMSO) was added into the cell medium. Cells were stimulated with 100 ng/ml NGF for various time points and lysed, then in vitro Ras and Rap1 activation assays were performed with GST-C-Raf-RBD or GST-RalGDS. B, quantitative analysis of Ras/Rap1 binding activity by OAG was normalized against that in sample of Me2SO treatment at 0 min and calculated as mean (±S.D.) from three independent experiments. C, OAG treatment rescues NGF-mediated C-Raf and B-Raf activation in PLC-{gamma}1-LIM cells. OAG- or Me2SO-treated cells were stimulated with NGF, and B-Raf and C-Raf were immunoprecipitated. In vitro Raf kinase assay was performed with Syntide II peptide as a substrate. D, OAG treatment rescues NGF-mediated MAP kinase activation in PLC-{gamma}1-LIM cells. Western blotting analysis of OAG or Me2SO-pretreated cells, which were stimulated with NGF, with phospho-ERK antibody (top panel). As a control, similar levels of MAP kinase activity were observed in empty vector-transfected control cells that were pretreated with OAG or Me2SO. OAG pretreatment elicits MAP kinase activation even in the absence of NGF stimulation. E, quantitative analysis of ERK activation by OAG from three independent experiments. Relative activity was normalized against that of the Me2SO-treated sample at 0 min and calculated as mean (±S.D.) of three determinations.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In this report, we show that the phospholipase activity of PLC-{gamma}1 is critical for the NGF-mediated MAPK signaling pathway in PC12 cells. Induction of stably transfected lipase inactive PLC-{gamma}1-(H335Q) markedly decreases the activation of Ras/C-Raf/MEK/MAPK and Rap1/B-Raf/MEK/MAPK cascades compared with the wild-type PLC-{gamma}1-transfected cells (Figs. 2, 3, 4). Treatment of PC12 cells with fibroblast growth factor or NGF leads to outgrowth of neurites and cessation of cell division (33), whereas treatment with EGF incurs cell proliferation. NGF stimulation results in a transient and sustained MAPK activation. By contrast, EGF provokes the evanescent activation of MAPK. Consistent with this idea, we failed to observe any defects in the activation of MAPK signaling in lipase inactive mutant cells upon EGF treatment (Fig. 2E), indicating that the phospholipase activity of PLC-{gamma}1 is not implicated in EGF-initiated MAPK signaling.

It has been shown before that a fibroblast growth factor receptor mutant (Tyr-766) unable to activate PLC-{gamma}1 elicits reduced activation of C-Raf/MAPK signaling probably through inhibiting Raf phosphorylation, which is mediated by PLC-{gamma}1-dependent protein kinase C (18). Moreover, pretreatment with U73122 [GenBank] results in 87% inhibition of NGF-mediated MAPK phosphorylation in TrkA-transfected Chinese hamster ovary cells, whereas it has no effect on NGF-stimulated Akt activation (34). NGF activates a DAG-regulated protein kinase, protein kinase C-{delta}, which is required for activation of the MAPK cascade and for neurite outgrowth. Protein kinase C-{delta} appears to act between Raf and MAPK/ERK in the pathway (28). These data strongly support our observations that the phospholipase activity of PLC-{gamma}1 is implicated in the NGF-mediated MAPK pathway.

Addition of OAG, a cell permeable synthetic DAG analog, rescues Ras, Rap1, and the MAP kinase cascade in PLC-{gamma}1-LIM cells (Fig. 5), suggesting that PLC-{gamma}1 regulates MAPK signaling upstream Ras/Rap1 activation probably through second messenger-mediated GEF. Several mammalian GEFs capable of activating Ras or Rap1 have been identified so far. For example, Sos, RasGRF (35, 36), and CalDAG-GEFII (also called RasGRP) are GEFs for Ras (37). The RasGRFs appear to be specialized for activating Ras in response to calcium signaling, via their calmodulin-binding IQ motifs (36, 38). C3G, cAMP-GEF (also called Epac), and CalDAG-GEF I are GEFs for Rap (39). CalDAG-GEFs can bind directly to and be activated by second messengers such as calcium and DAG. The second messenger-mediated GEF may represent a new class of GEFs, distinct from receptor-tyrosine kinase/adaptor molecule-associated GEFs. In addition, these GEFs display very different and restricted central nervous system expression patterns, suggesting that they may act as distinct regulators of neuronal signaling (11). NGF receptor TrkA may induce multiple signals to activate Ras and Rap1, one of which might involve PLC-{gamma}1 activation. Complete activation of Ras and Rap1 pathways needs both Shc/fibroblast growth factor receptor substrate 2-dependent and PLC-{gamma}1-dependent stimulation of upstream GEFs.

At glutamatergic synapses, Ras has been implicated as a major target for calcium signaling to MAP kinases, through stimulation of RasGRF (38) or via tyrosine kinases such Src or Pyk2 (40). Stimulation of both metabotropic and N-methyl-D-aspartate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid postsynaptic receptors leads to calcium influx and elevation of cAMP and DAG, which can regulate both Ras and Rap-dependent action through RasGRF and CalDAG-GEF (11). In parallel to the receptor-tyrosine kinase phosphotyrosine docking site for the SH2 domain containing adaptor molecules (e.g. Grb2, Shc, and Crk), it has been shown that PLC-{gamma}1 can associate directly with phosphotyrosine sites on N-methyl-D-aspartate channels via its SH2 domain (41). Existence of multiple MAPK signaling in postsynaptic density might allow neurons to regulate the kinetics of ERK activation. The ability to temporally regulate Ras- and Rap-dependent signaling has been demonstrated to regulate NGF-mediate gene expression and cell physiology of PC12 cells (32).


   FOOTNOTES
 
* The work was supported by American Cancer Society Grant RSG-04-077-01-TBE (to K. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom all correspondence should be addressed. Tel.: 404-712-2814; Fax: 404-712-2979; E-mail: kye{at}emory.edu.

1 The abbreviations used are: PLC-{gamma}1, phospholipase C-{gamma}1; LIM, lipase inactive mutant; DAG, diacylglycerol; SH2, Src homology 2; NGF, nerve growth factor; GST, glutathione S-transferase; MAP kinase, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinases; GEF, guanine nucleotide exchange factor; OAG, 1-oleyl-2-acetylglycerol, RBDs, Ras/Rap1 binding domain; EGF, epidermal growth factor; WT, wild-type. Back


   ACKNOWLEDGMENTS
 
We are indebted to Dr. J. L. Bos at Utrecht University, The Netherlands, and Dr. Mike Gold at the University of British Columbia, Canada, for GST-RalGDS construct.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ji, Q. S., Winnier, G. E., Niswender, K. D., Horstman, D., Wisdom, R., Magnuson, M. A., and Carpenter, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2999-3003[Abstract/Free Full Text]
  2. Thackeray, J. R., Gaines, P. C., Ebert, P., and Carlson, J. R. (1998) Development 125, 5033-5042[Abstract]
  3. Smith, M. R., Ryu, S. H., Suh, P. G., Rhee, S. G., and Kung, H. F. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3659-3663[Abstract/Free Full Text]
  4. Smith, M. R., Liu, Y. L., Kim, H., Rhee, S. G., and Kung, H. F. (1990) Science 247, 1074-1077[Abstract/Free Full Text]
  5. Smith, M. R., Liu, Y. L., Matthews, N. T., Rhee, S. G., Sung, W. K., and Kung, H. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6554-6558[Abstract/Free Full Text]
  6. Smith, M. R., Liu, Y. L., Kim, S. R., Bae, Y. S., Kim, C. G., Kwon, K. S., Rhee, S. G., and Kung, H. F. (1996) Biochem. Biophys. Res. Commun. 222, 186-193[CrossRef][Medline] [Order article via Infotrieve]
  7. Huang, P. S., Davis, L., Huber, H., Goodhart, P. J., Wegrzyn, R. E., Oliff, A., and Heimbrook, D. C. (1995) FEBS Lett. 358, 287-292[CrossRef][Medline] [Order article via Infotrieve]
  8. Ye, K., Hurt, K. J., Wu, F. Y., Fang, M., Luo, H. R., Hong, J. J., Blackshaw, S., Ferris, C. D., and Snyder, S. H. (2000) Cell 103, 919-930[CrossRef][Medline] [Order article via Infotrieve]
  9. Ye, K., Aghdasi, B., Luo, H. R., Moriarity, J. L., Wu, F. Y., Hong, J. J., Hurt, K. J., Bae, S. S., Suh, P. G., and Snyder, S. H. (2002) Nature 415, 541-544[CrossRef][Medline] [Order article via Infotrieve]
  10. Patterson, R. L., van Rossum, D. B., Ford, D. L., Hurt, K. J., Bae, S. S., Suh, P. G., Kurosaki, T., Snyder, S. H., and Gill, D. L. (2002) Cell 111, 529-541[CrossRef][Medline] [Order article via Infotrieve]
  11. Grewal, S. S., York, R. D., and Stork, P. J. (1999) Curr. Opin. Neurobiol. 9, 544-553[CrossRef][Medline] [Order article via Infotrieve]
  12. Marais, R., Wynne, J., and Treisman, R. (1993) Cell 73, 381-393[CrossRef][Medline] [Order article via Infotrieve]
  13. Janknecht, R., Ernst, W. H., Pingoud, V., and Nordheim, A. (1993) EMBO J. 12, 5097-5104[Medline] [Order article via Infotrieve]
  14. Gille, H., Kortenjann, M., Thomae, O., Moomaw, C., Slaughter, C., Cobb, M. H., and Shaw, P. E. (1995) EMBO J. 14, 951-962[Medline] [Order article via Infotrieve]
  15. Kao, S., Jaiswal, R. K., Kolch, W., and Landreth, G. E. (2001) J. Biol. Chem. 276, 18169-18177[Abstract/Free Full Text]
  16. Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., and Kaplan, D. R. (1994) Neuron 12, 691-705[CrossRef][Medline] [Order article via Infotrieve]
  17. Obermeier, A., Bradshaw, R. A., Seedorf, K., Choidas, A., Schlessinger, J., and Ullrich, A. (1994) EMBO J. 13, 1585-1590[Medline] [Order article via Infotrieve]
  18. Huang, J., Mohammadi, M., Rodrigues, G. A., and Schlessinger, J. (1995) J. Biol. Chem. 270, 5065-5072[Abstract/Free Full Text]
  19. Kim, M. J., Chang, J. S., Park, S. K., Hwang, J. I., Ryu, S. H., and Suh, P. G. (2000) Biochemistry 39, 8674-8682[CrossRef][Medline] [Order article via Infotrieve]
  20. Pei, Z., Maloney, J. A., Yang, L., and Williamson, J. R. (1997) Arch. Biochem. Biophys. 345, 103-110[CrossRef][Medline] [Order article via Infotrieve]
  21. Scholler, J. K., Perez-Villar, J. J., O'Day, K., and Kanner, S. B. (2000) Eur. J. Immunol. 30, 2378-2387[CrossRef][Medline] [Order article via Infotrieve]
  22. Yablonski, D., Kadlecek, T., and Weiss, A. (2001) Mol. Cell. Biol. 21, 4208-4218[Abstract/Free Full Text]
  23. Goldschmidt-Clermont, P. J., Kim, J. W., Machesky, L. M., Rhee, S. G., and Pollard, T. D. (1991) Science 251, 1231-1233[Abstract/Free Full Text]
  24. Muslin, A. J., MacNicol, A. M., and Williams, L. T. (1993) Mol. Cell. Biol. 13, 4197-4202[Abstract/Free Full Text]
  25. Franke, B., Akkerman, J. W., and Bos, J. L. (1997) EMBO J. 16, 252-259[CrossRef][Medline] [Order article via Infotrieve]
  26. Sultzman, L., Ellis, C., Lin, L. L., Pawson, T., and Knopf, J. (1991) Mol. Cell. Biol. 11, 2018-2025[Abstract/Free Full Text]
  27. Kim, H. K., Kim, J. W., Zilberstein, A., Margolis, B., Kim, J. G., Schlessinger, J., and Rhee, S. G. (1991) Cell 65, 435-441[CrossRef][Medline] [Order article via Infotrieve]
  28. Corbit, K. C., Foster, D. A., and Rosner, M. R. (1999) Mol. Cell. Biol. 19, 4209-4218[Abstract/Free Full Text]
  29. Oshima, M., Sithanandam, G., Rapp, U. R., and Guroff, G. (1991) J. Biol. Chem. 266, 23753-23760[Abstract/Free Full Text]
  30. Stephens, R. M., Sithanandam, G., Copeland, T. D., Kaplan, D. R., Rapp, U. R., and Morrison, D. K. (1992) Mol. Cell. Biol. 12, 3733-3742[Abstract/Free Full Text]
  31. Jaiswal, R. K., Weissinger, E., Kolch, W., and Landreth, G. E. (1996) J. Biol. Chem. 271, 23626-23629[Abstract/Free Full Text]
  32. York, R. D., Yao, H., Dillon, T., Ellig, C. L., Eckert, S. P., McCleskey, E. W., and Stork, P. J. (1998) Nature 392, 622-626[CrossRef][Medline] [Order article via Infotrieve]
  33. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428[Abstract/Free Full Text]
  34. Zapf-Colby, A., Eichhorn, J., Webster, N. J., and Olefsky, J. M. (1999) Oncogene 18, 4908-4919[CrossRef][Medline] [Order article via Infotrieve]
  35. Cen, H., Papageorge, A. G., Vass, W. C., Zhang, K. E., and Lowy, D. R. (1993) Mol. Cell. Biol. 13, 7718-7724[Abstract/Free Full Text]
  36. Fam, N. P., Fan, W. T., Wang, Z., Zhang, L. J., Chen, H., and Moran, M. F. (1997) Mol. Cell. Biol. 17, 1396-1406[Abstract]
  37. Ebinu, J. O., Bottorff, D. A., Chan, E. Y., Stang, S. L., Dunn, R. J., and Stone, J. C. (1998) Science 280, 1082-1086[Abstract/Free Full Text]
  38. Farnsworth, C. L., Freshney, N. W., Rosen, L. B., Ghosh, A., Greenberg, M. E., and Feig, L. A. (1995) Nature 376, 524-527[CrossRef][Medline] [Order article via Infotrieve]
  39. Gotoh, T., Hattori, S., Nakamura, S., Kitayama, H., Noda, M., Takai, Y., Kaibuchi, K., Matsui, H., Hatase, O., Takahashi, H., Kurata, T., and Matsuda, M. (1995) Mol. Cell. Biol. 15, 6746-6753[Abstract]
  40. Finkbeiner, S., and Greenberg, M. E. (1996) Neuron 16, 233-236[CrossRef][Medline] [Order article via Infotrieve]
  41. Gurd, J. W., and Bissoon, N. (1997) J. Neurochem. 69, 623-630[Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
L. Zhou, S. J. Martinez, M. Haber, E. V. Jones, D. Bouvier, G. Doucet, A. T. Corera, E. A. Fon, A. H. Zisch, and K. K. Murai
EphA4 Signaling Regulates Phospholipase C{gamma}1 Activation, Cofilin Membrane Association, and Dendritic Spine Morphology
J. Neurosci., May 9, 2007; 27(19): 5127 - 5138.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
Y. Dwivedi, A. C. Mondal, H. S. Rizavi, G. Faludi, M. Palkovits, A. Sarosi, R. R. Conley, and G. N. Pandey
Differential and brain region-specific regulation of rap-1 and epac in depressed suicide victims.
Arch Gen Psychiatry, June 1, 2006; 63(6): 639 - 648.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. T. Buckley, F. Sekiya, Y. J. Kim, S. G. Rhee, and K. K. Caldwell
Identification of Phospholipase C-{gamma}1 as a Mitogen-activated Protein Kinase Substrate
J. Biol. Chem., October 1, 2004; 279(40): 41807 - 41814.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/52/52497    most recent
M306744200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rong, R.
Right arrow Articles by Ye, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rong, R.
Right arrow Articles by Ye, K.
Social Bookmarking
Add to CiteULike   Add to Complore